InsiderPulse
Dashboard

ALKS

Alkermes plc

Health CareRussell 2000

Alkermes plc insider trading

Alkermes plc files with the SEC as a Pharmaceutical Preparations company headquartered in Dublin 4, L2. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent ALKS insider transactions

6 insiders traded ALKS on the open market between Mar 02, 2026 and Sep 03, 2026 — 20 sales worth $6.6M, of which 18 were pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$6.6M

18 of 20 on a 10b5-1 plan

Net
−$6.6M
Insiders
6

Open-market purchases (code P) and sales (code S) from Alkermes plc's own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 22, 2026. The live dashboard shows new filings the moment they clear.

Every ALKS Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

ALKS insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 7 insiders traded ALKS on the open market: 0 purchases and 40 sales worth $26.8M, 39 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 23 sales ($6.2M), by 6 insiders.

QuarterBoughtSold
Q2 2026—−$2M8 sales · 7 on a plan
Q1 2026—−$3.5M11 sales · all on a plan
Q4 2025—−$786.8K4 sales · all on a plan
Q3 2025——
Q2 2025—−$210.1K2 sales · all on a plan
Q1 2025—−$15.3M8 sales · all on a plan
Q4 2024—−$5M7 sales · all on a plan
Q3 2024——
Largest sale
−$5.6M of ALKS by Hopkinson Craig C. (EVP R&D, Chief Medical Officer) on Feb 12, 2025, under a 10b5-1 plan.

Open-market transactions through Jun 30, 2026most recent first

  • Hopkinson Craig C.10b5-1

    EVP R&D, Chief Medical Officer

    −$375K

    Jun 01, 2026

    9,000 sh · $41.67

  • Parisi Samuel Joseph

    VP, Finance (Interim PAO)

    −$687K

    May 29, 2026

    16,217 sh · $42.36

  • Hopkinson Craig C.10b5-1

    EVP R&D, Chief Medical Officer

    −$300.6K

    May 01, 2026

    9,000 sh · $33.40

  • Hopkinson Craig C.10b5-1

    EVP R&D, Chief Medical Officer

    −$319.6K

    Apr 01, 2026

    9,000 sh · $35.51

  • Gaffin David Joseph10b5-1

    EVP, CLO, Alkermes, Inc.

    −$60.5K

    Mar 03, 2026

    2,034 sh · $29.76

  • Hopkinson Craig C.10b5-1

    EVP R&D, Chief Medical Officer

    −$267.5K

    Mar 02, 2026

    9,000 sh · $29.72

  • Gaffin David Joseph10b5-1

    EVP, CLO, Alkermes, Inc.

    −$59.6K

    Mar 02, 2026

    2,034 sh · $29.29

  • Cooke Shane10b5-1

    Director

    −$1.1M

    Feb 02, 2026

    32,113 sh · $34.78

  • Cooke Shane10b5-1

    Director

    −$998.8K

    Feb 02, 2026

    29,087 sh · $34.34

  • Hopkinson Craig C.10b5-1

    EVP R&D, Chief Medical Officer

    −$171.2K

    Feb 02, 2026

    5,000 sh · $34.24

  • Hopkinson Craig C.10b5-1

    EVP R&D, Chief Medical Officer

    −$134.2K

    Feb 02, 2026

    4,000 sh · $33.54

  • Hopkinson Craig C.10b5-1

    EVP R&D, Chief Medical Officer

    −$150K

    Jan 08, 2026

    5,000 sh · $30.00

  • Hopkinson Craig C.10b5-1

    EVP R&D, Chief Medical Officer

    −$112K

    Jan 02, 2026

    4,000 sh · $28.00

  • Hopkinson Craig C.10b5-1

    EVP R&D, Chief Medical Officer

    −$112.4K

    Dec 03, 2025

    3,748 sh · $30.00

  • Hopkinson Craig C.10b5-1

    EVP R&D, Chief Medical Officer

    −$117.2K

    Dec 01, 2025

    4,000 sh · $29.30

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Alkermes plc company record

SEC industry classification
Pharmaceutical Preparations
Headquarters
Dublin 4, L2
Listed on
Nasdaq
SEC Central Index Key
0001520262
Previously filed as
ANTLER SCIENCE TWO PLC

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought ALKS

What the stock actually did in the 90 days following each open-market purchase

Don't check ALKS — let it ping you

Get told the moment an insider moves on ALKS

Pro watches Alkermes plc for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add ALKS to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track ALKS on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read ALKS insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

APLSARVNBBIOCYTKDAWNDYNIMVTINSMIOVAITCIKYMRLEGN
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are ALKS insiders buying or selling?
Between Mar 02, 2026 and Sep 03, 2026, 6 Alkermes plc insiders made no open-market purchases and 20 sales worth $6.6M, a net sale of $6.6M. 18 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much ALKS stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 7 Alkermes plc insiders made no open-market purchases and 40 sales worth $26.8M. 39 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 23 sales ($6.2M). The largest sale was Hopkinson Craig C. selling $5.6M on Feb 12, 2025.
What was the largest recent ALKS insider trade?
snyderman nancy lynn MD (Director) sold $2.2M of ALKS stock on Aug 03, 2026 at about $50.35 a share.
When did an insider last buy ALKS shares?
No open-market purchase by a Alkermes plc insider appears in the filings from Mar 02, 2026 to Sep 03, 2026 — every recorded open-market transaction in that period was a sale.
Where does ALKS insider trading data come from?
From the Form 4 filings Alkermes plc's officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.